Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

The present study aimed to determine the safety and activity of the histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia (WM). Eligibility criteria included patients with relapsed/refractory WM with any number of prior therapies. Patients rece...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ghobrial, Irene M., Campigotto, Federico, Murphy, Timothy J., Boswell, Erica N., Banwait, Ranjit, Azab, Feda, Chuma, Stacey, Kunsman, Janet, Donovan, Amanda, Masood, Farzana, Warren, Diane, Rodig, Scott, Anderson, Kenneth C., Richardson, Paul G., Weller, Edie, Matous, Jeffrey
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2013
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3578951/
https://ncbi.nlm.nih.gov/pubmed/23287861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-06-439307
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars